Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: A phase II study

Leukemia and Lymphoma

Volumn 36, Issue 1-2, 1999, Pages 57-65

  Giles, Francis J ^a   Obrien, Susan M ^a   Santini, Valeria ^a   Gandhi, Varsha ^a   Plunkett, William ^a   Seymour, John F ^a   Robertson, Lester E ^a   Kantarjian, Hagop M ^a   Keating, Michael J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Arabinosyl cytosine; Chronic lymphocyte leukemia; cis platinum; CLL; Combination chemotherapy; Failire regimen; Fludarabine; Resistant disease

Indexed keywords

CISPLATIN; CYTARABINE; FLUDARABINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY FAILURE; LYMPHOPROLIFERATIVE DISEASE; MALE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SURVIVAL TIME;

EID: 0033406619     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909145949     Document Type: Article

References (34)

1. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989: 74: 19-25.
2. Keating MJ, Kantarjian H, O'Brien S. et al. Fludanihine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991; 9: 44-9.
3. Keating MJ, O'Brien S, Kantarjian H, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878-84.
4. Frankfurt OS, Byrnes JJ, Villa L. Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients. Leuk Res 1997; 21: 9-16.
5. Morabito F, Filangeri M, Callea I, et al. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs. Haematologica 1997; 82: 16-20.
6. Younes A, Snell V, Consoli U, et al. Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia. Br J Haematol 1998; 100: 135-41.
7. Thomas A, El Rouby S, Reed JC, et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996; 12: 1055-62.
8. Bromidge TJ, Turner DL, Howe DJ, Johnson SA, Rule SA. In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues-correlation with clinical course. Leukemia 1998; 12: 1230-5.
9. McConkey DJ, Chandra J, Wright S, et al. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 1996; 156: 2624-30.
10. Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 1988; 48: 329-34.
11. Gandhi V, Nowak B, Keating MJ, Plunkett W. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood 1989; 74: 2070-5.
12. Gandhi V, Kemena A, Keating MJ, Plunkett W. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 1992; 52: 897-903.
13. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993; 11: 116-24.
14. Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Semin Oncol 1990; 17: 3-17.
15. Keating MJ, O'Brien S, Robertson LE, et al. New initiatives with fludarabine monophosphate in hematologic malignancies. Semin Oncol 1993; 20: 13-20.
16. Yang LY, Li L, Keating MJ, Plunkett W. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol 1995; 47: 1072-9.
17. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169-76.
18. Cheson BD, Bennett JM, Rai KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 1988: 29: 152-63.
19. Robertson LE, Huh YO, Butler JJ, et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 1992; 80: 29-36.
20. Gehan EA. A generalized two-sample Wilcoxon test for doubly censored data. Biometrika 1965; 52: 650-3.
21. Gandhi V, Kemena A, Keating MJ, Plunkett W. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymphoma 1993; 10: 49-56.
22. O'Brien S, Kantarjian H, Beran M. et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment [see comments]. Blood 1993; 82: 1695-700.
23. Keating MJ, Estey E, O'Brien S, Kantarjian H, Robertson LE, Plunkett W. Clinical experience with fludarabine in leukaemia. Drugs 1994; 47: 39-49.
24. O'Brien S, Kantarjian H, Estey E, et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy [see comments]. N Engl J Med 1994; 330: 319-22.
25. Delannoy A, Ferrant A, Martiat P, et al. 2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukaemia. Nouv Rev Fr Hematol 1994; 36: 311-5.
26. Ikizawa K, Kajiwara K, Koshio T, Matsuura N, Yanagihara Y. Inhibition of IL-4 receptor upregulation on B cells by antisense oligodeoxynucleotide suppresses IL-4-induced human IgE production. Clin Exp Immunol 1995; 100: 383-9.
27. Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997; 349: 1137-41.
28. Wang D, Freeman GJ, Levine H, Ritz J, Robertson MJ. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br. J Haematol 1997; 97: 409-17.
29. Iciek LA, Delphin SA, Stavnezer J. CD40 cross-linking induces Ig epsilon germline transcripts in B cells via activation of NF-kappaB: synergy with IL-4 induction. J Immunol 1997; 158: 4769-79.
30. Morabito F, Callea I, Console G, et al. The in vitro cytotoxic effect of mitoxantrone in combination with fludarabine or pentostatin in B-cell chronic lymphocytic leukemia. Haematologica 1997; 82: 560-5.
31. O'Brien S. Clinical challenges in chronic lymphocytic leukemia. Semin Hematol 1998; 35: 22-6.
32. Byrd JC, Rai KR, Sausville EA, Grever MR. Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals. Semin Oncol 1998; 25: 65-74.
33. Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998; 92: 3804-16.
34. Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJ, Catovsky D. Subcutaneous CAMPATH-IH in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 1997; 96: 617-4.